Nonsurgical Management of Osteolysis
Authors:
- Carl T TalmoCTCarl T Talmo
- Arun S ShanbhagASArun S Shanbhag
- Harry E RubashHRHarry E Rubash
- 1 December 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 453, 254-264
Abstract
Osteolysis remains a common mode of total hip arthroplasty failure. In vitro and animal models have been used to determine the pathophysiology of osteolysis by carefully dissecting the biochemical pathways leading to particulate wear debris and periprosthetic bone loss. Numerous cytokines and inflammatory mediators, including TNF-alpha and IL-1, are critical participants in this cascade and may represent prime targets for pharmacologic intervention. Osteoclasts, the end effector cells involved in the osteolytic process, also represent potential targets. Cell surface receptors on osteoclast precursors, such as receptor activator of NF-kappaB (RANK) (on osteoclasts) and RANK-ligand (RANKL) (on stromal cells), provide opportunities to arrest osteoclast maturation. Enhancing the naturally occurring osteoprotegerin is another recent attempt at modulating osteoclast behavior and a possible target for pharmacologic therapies. Other nonoperative strategies include intercepting tumor necrosis factor-alpha activity, interfering with the RANK-RANKL interaction necessary for osteoclast development and maturation, bisphosphonate therapy, and using viral vectors to deliver genes. Although each of these approaches has potential benefits, there are substantial challenges to effective implementation. Until there is convincing evidence of efficacy in human clinical trials, we recommend vigilant screening and appropriate surgery with component loosening or substantial likelihood of loosening, periprosthetic fracture, or major bone loss.Keywords
This publication has 91 references indexed in Scilit:
- Recombinant Osteoprotegerin for Juvenile Paget's DiseaseNew England Journal of Medicine, 2005
- Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplastyJournal of Orthopaedic Science, 2005
- Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysisGene Therapy, 2004
- Local infusion of FGF‐2 enhances bone ingrowth in rabbit chambers in the presence of polyethylene particlesJournal of Biomedical Materials Research Part A, 2003
- Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in RatsJournal of Bone and Mineral Research, 2003
- A Rat Model for Testing Pharmacologic Treatments of Pressure-Related Bone LossClinical Orthopaedics and Related Research, 2003
- PMMA particles and pressure—a study of the osteolytic properties of two agents proposed to cause prosthetic looseningJournal of Orthopaedic Research, 2003
- Collagen crosslinked N‐telopeptides as markers for evaluating particulate osteolysis: A preliminary studyJournal of Orthopaedic Research, 2000
- Migration, Particles, and Fluid PressureClinical Orthopaedics and Related Research, 1998
- Medical Management of OsteoporosisClinical Orthopaedics and Related Research, 1998